B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof

Abstract

The invention discloses a B7.1-CD19scFv merge gene engineering protein and usage to treat B lymphocyte leukosis, lymph tumor, which comprises the following parts: human B7.1 external cell area, antihuman CD19 monoclonal antibody heavy chain and light chain variable area gene.

Description

technical field [0001] The invention relates to a fusion genetic engineering protein, especially a B7.1-CD19scFv fusion genetic engineering protein for treating B lymphocytic leukemia and lymphoma and its application. Background technique [0002] The immune response mediated by tumor-specific T cells is the main means for the body to eliminate tumor cells. In a normal immune response, antigen-specific T cells need to be stimulated by at least two signals to proliferate and generate an immune response to the antigen. The first signal is antigen-specific and is mediated by T-cell receptors (TCR) and MHC class I or II molecules that bind specific antigens, and the second signal is by antigen-presenting cells (APCs) or other It is mediated by the reaction between co-stimulatory molecules (such as B7 molecules) on the cell surface and T cell surface molecules (such as CD28). Tumor cells escape the body's immune surveillance by down-regulating the expression of molecules involve...

AI Technical Summary

Problems solved by technology

Loss of the second signal results in T cell "immunocompetence," preventing clonal expansion of tumor-specific cytotoxic T cells (CTLs)

[0006] Studies have shown that the expression of immune co-stimulatory molecule B7.1 on the surface of ALL leukemia cells is reduced or even absent, resulting in the inability of leukemia cells to be effectively recognized and killed by cytotoxic T cells (CTL)

Images